Business Context and Reporting Period
Company: Anika Therapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2011
Business Overview: Anika develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair based on hyaluronic acid (HA). The company operates in orthobiologics, dermal, ophthalmic, surgical, and veterinary markets. It recently acquired Anika S.r.l., an Italian subsidiary, expanding its product portfolio and geographic reach.
Key Financial Metrics
| Metric | Q1 2011 | Q1 2010 |
|---|---|---|
| Total Revenue | $11,737,679 | $12,466,087 |
| Net Income | $324,412 | $714,280 |
| Diluted EPS | $0.02 | $0.05 |
| Product Gross Margin | 49% | 56% |
| Operating Cash Flow | $1,285,947 | $19,485 |
| Cash and Equivalents (End of Period) | $29,078,810 | $23,167,641 |
| Total Debt Outstanding | $12,400,000 | $12,800,000 |
| Working Capital | $37,000,000 (approx.) | $37,000,000 (approx.) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 6% year-over-year. Product revenue fell 5% to $11.06 million, primarily due to a manufacturing equipment failure at the Woburn, MA facility that delayed shipments of approximately $1.4 million in ophthalmic and joint health products.
- Profitability Compression: Net income dropped 55% to $324,412. Product gross margin declined from 56% to 49% due to the loss of an in-process product batch (inventory write-down of ~$450,000) and the aforementioned shipment delays.
- Segment Performance:
- Ophthalmic: Revenue plummeted 65% to $897,808, driven by the manufacturing disruption and the transition of a major contract (Bausch & Lomb) to a new supplier.
- Orthobiologics: Revenue increased 16% to $8.04 million, led by growth in joint health products (ORTHOVISC, MONOVISC).
- Surgical: Revenue surged 92% to $1.11 million, attributed to order timing for anti-adhesion and ENT products.
- Expense Management: Operating expenses decreased slightly (1%) to $11.18 million. R&D expenses fell 18% due to project timing, while SG&A expenses declined 6% due to operational streamlining.
Outlook, Risks, and Management Commentary
- Manufacturing Transition: The company plans to transfer significant manufacturing from Woburn, MA, to a new facility in Bedford, MA. FDA approval for the Bedford facility is now expected in early 2012, delaying the full transition. This will result in increased annual depreciation of approximately $1.8 million once operational.
- Product Pipeline:
- MONOVISC: The company is awaiting FDA approval for its single-injection osteoarthritis product. An Advisory Panel review has been requested to resolve submission deficiencies.
- CINGAL: A next-generation osteoarthritis product is in development.
- Legal Contingencies:
- Genzyme Litigation: Genzyme alleges patent infringement regarding MONOVISC. Anika denies liability and has not accrued for potential losses, deeming them not probable.
- Artes Bankruptcy: A former distributor's trustee is seeking recovery of $359,768 in payments. Anika contests this claim and has not accrued for the loss.
- Liquidity: The company maintains strong liquidity with $29.1 million in cash. It expects to fund operations and capital expenditures from existing resources and operating cash flows for the foreseeable future.
Investor Verification Checklist
- Manufacturing Timeline: Verify the status of the Bedford, MA facility validation and the specific date for FDA approval to begin shipping products from the new location.
- MONOVISC Regulatory Status: Confirm the scheduling and outcome of the FDA Orthopedic Advisory Panel review regarding MONOVISC approval.
- Legal Exposure: Monitor developments in the Genzyme patent infringement lawsuit and the Artes bankruptcy preference claim for any changes in management's assessment of probable losses.
- Bausch & Lomb Contract: Track the revenue impact of the transition away from the Bausch & Lomb supply agreement and the performance of the new AnikaVisc product.
- Inventory Valuation: Review future quarters for any additional inventory write-downs related to the Woburn facility equipment issues or product obsolescence.